trial
as of 2026-07-01SB-773812 Administered In Adults With Schizophrenia
NCTId NCT00259870
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
338 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2005-09
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
GlaxoSmithKlineLead Sponsor
Sites
45 total
Birmingham, United StatesCerritos, United StatesGarden Grove, United StatesNational City, United StatesSan Diego, United StatesUpland, United StatesNew Haven, United StatesWashington D.C., United StatesNorth Miami, United StatesClementon, United StatesKenilworth, United StatesAlbuquerque, United States
Facts & assertions
3 sourced
Enrollment
338
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
lead_sponsor
company
indication
indication
indication